Welgene Biotech Co.,Ltd. (TPEX:6661)
Taiwan
· Delayed Price · Currency is TWD 18.15
-0.15 (-0.82%)
Apr 29, 2026, 1:30 PM CST
Welgene Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 1.33 | 1.11 | -2.65 | 9.55 | 13.7 | Upgrade
|
| Depreciation & Amortization | 27.79 | 28.72 | 27.06 | 18.86 | 19.02 | Upgrade
|
| Other Amortization | - | 0.08 | 0.19 | 0.19 | 0.19 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.18 | -0.37 | 0.11 | - | 0.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | -2.1 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | 4.19 | -5.04 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | - | 2.89 | Upgrade
|
| Stock-Based Compensation | - | - | - | - | 0 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.07 | 0.15 | -0.6 | -1.41 | 0.19 | Upgrade
|
| Other Operating Activities | 2.44 | 4.49 | -9.62 | 3.46 | -5.33 | Upgrade
|
| Change in Accounts Receivable | -4.05 | 4.04 | -1.06 | 36.6 | -22.37 | Upgrade
|
| Change in Inventory | -1.41 | 12.76 | -10.64 | -8.85 | -7.99 | Upgrade
|
| Change in Accounts Payable | 8.26 | -0.47 | -1.88 | 6.46 | -2.92 | Upgrade
|
| Change in Unearned Revenue | -1.93 | 9.95 | -0.78 | -17.08 | 23.11 | Upgrade
|
| Change in Other Net Operating Assets | 5.19 | -4.38 | -0.49 | -0.54 | -4.22 | Upgrade
|
| Operating Cash Flow | 35.27 | 56.08 | -0.37 | 51.43 | 11.25 | Upgrade
|
| Operating Cash Flow Growth | -37.11% | - | - | 357.29% | -73.08% | Upgrade
|
| Capital Expenditures | -41.34 | -4.81 | -27.73 | -26.86 | -4.38 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.48 | 0.55 | - | - | 0.24 | Upgrade
|
| Cash Acquisitions | - | - | -12.8 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.7 | - | - | - | - | Upgrade
|
| Investment in Securities | 10.5 | -41.37 | 46.22 | -42.16 | -5.67 | Upgrade
|
| Other Investing Activities | -1.72 | 0.43 | 0.32 | 1.03 | -0.53 | Upgrade
|
| Investing Cash Flow | -32.78 | -45.19 | 6 | -67.99 | -10.34 | Upgrade
|
| Short-Term Debt Issued | 3 | - | - | - | 5.56 | Upgrade
|
| Long-Term Debt Issued | 80 | 2 | 45 | - | - | Upgrade
|
| Total Debt Issued | 83 | 2 | 45 | - | 5.56 | Upgrade
|
| Short-Term Debt Repaid | - | -2 | -0.21 | -1.35 | - | Upgrade
|
| Long-Term Debt Repaid | -31.69 | -24.86 | -18.38 | -11.97 | -11.35 | Upgrade
|
| Total Debt Repaid | -31.69 | -26.86 | -18.59 | -13.33 | -11.35 | Upgrade
|
| Net Debt Issued (Repaid) | 51.31 | -24.86 | 26.41 | -13.33 | -5.79 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 69.99 | Upgrade
|
| Common Dividends Paid | - | - | -4.23 | -11.29 | -25.68 | Upgrade
|
| Other Financing Activities | -2.95 | -0.66 | 1.72 | -0 | -0 | Upgrade
|
| Financing Cash Flow | 48.36 | -25.52 | 23.91 | -24.62 | 38.52 | Upgrade
|
| Net Cash Flow | 50.84 | -14.64 | 29.54 | -41.18 | 39.43 | Upgrade
|
| Free Cash Flow | -6.08 | 51.27 | -28.1 | 24.57 | 6.87 | Upgrade
|
| Free Cash Flow Growth | - | - | - | 257.63% | -80.84% | Upgrade
|
| Free Cash Flow Margin | -1.62% | 15.90% | -10.02% | 7.63% | 2.20% | Upgrade
|
| Free Cash Flow Per Share | -0.27 | 2.20 | -1.21 | 1.05 | 0.30 | Upgrade
|
| Cash Interest Paid | 3.27 | 2.66 | 1.86 | 0.19 | 0.17 | Upgrade
|
| Cash Income Tax Paid | -2.29 | 0.11 | 7.03 | 0.28 | 7.05 | Upgrade
|
| Levered Free Cash Flow | -12.09 | 46.79 | -17.18 | 25.9 | 2.14 | Upgrade
|
| Unlevered Free Cash Flow | -9.96 | 48.64 | -15.54 | 26.08 | 2.41 | Upgrade
|
| Change in Working Capital | 6.06 | 21.91 | -14.85 | 16.59 | -14.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.